Cohort Selection In Utero against Male Twins and Childhood Cancers: A Population-Based Register Study

Background: Cancer ranks as the second leading cause of death among children ages 1 to 14 years in the United States. Previous research finds that strong cohort selection in utero against males precedes a reduction in live-born males considered frail. We examine whether such cohort selection in utero may similarly affect the frequency of childhood cancers among male live births. Methods: We examined 1,368 childhood cancers among males born in Sweden over 144 months, from January 1990 to December 2001, and followed to age 15 in the Swedish Cancer Registry. We retrieved the count of male twins by birth month from the Swedish Birth Registry. Weapplied autoregressive, integrated, moving average time-series methods to identify and control for temporal patterns in monthly childhood cancers and to evaluate robustness of results. Results: Fewer childhood cancers occur among monthly male birth cohorts with elevated selection in utero (i.e., a low count of liveborn male twins). This association appears in the concurrent month (coef = 0.04; 95% CI, 0.001-0.079) as well as in the following month in which most births from the twin's conception cohort are scheduled to be born (coef = 0.055; 95% CI, 0.017-0.094). Conclusions: Elevated cohort selection in utero may reduce the number of frail male gestations that would otherwise have survived to birth and received a cancer diagnosis during childhood. Impact: This novel result warrants further investigation of prenatal exposures, including those at the population level, that may induce cohort selection in utero for some cancer types but not others.

Automated summary

The study suggests that cohort selection in utero may reduce the occurrence of childhood cancers among male live births, potentially affecting the number of frail male gestations that would have survived to birth and received a cancer diagnosis during childhood. Further investigation of prenatal exposures inducing cohort selection in utero for certain cancer types is warranted.